Q-omics provides the consensus-scored CICP7 profile across patient tissues and cancer cell-line models. CICP7 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, CICP7 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, CICP7 RNA expression shows 4,756 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight ESCA, KIRP, and KIRC as cancer lineages where CICP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP7 survival associations across molecular data types. CICP7 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP7 RNA expression–survival associations across cancer types. High CICP7 expression shows unfavorable associations in ESCA, UVM, COAD, DLBC, THCA and LUSC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ESCA as the clearest survival context for CICP7 RNA expression.
This table summarizes CICP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CICP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP7 shows lower tumor expression in LUSC and higher tumor expression in KIRP and STAD. The KIRP box plot shows higher CICP7 RNA expression in tumor versus normal tissue (log2 FC = +0.011, t-test p = .037).
This table shows molecular features associated with CICP7 in patient tissues and cancer cell lines. In patient samples, CICP7 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
